Your browser doesn't support javascript.
loading
Design, Synthesis, Pharmacological Activities, Structure-Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones.
Sicak, Yusuf; Aktar, Bedriye Seda Kursun; Yilmaz, Gizem Tatar; Öztürk, Fatma Aydogmus; Öztürk, Mehmet; Tok, Tugba Taskin; Emre, Emine Elçin Oruç.
Afiliação
  • Sicak Y; Department of Medicinal and Aromatic Plants, Köycegiz Vocational School, Mugla Sitki Koçman University, Köycegiz, Mugla 48800, Turkey.
  • Aktar BSK; Department of Hair Care and Beauty Services, Yesilyurt Vocational School, Malatya Turgut Özal University, Malatya 44210, Turkey.
  • Yilmaz GT; Department of Biostatistics and Medical Informatics, Faculty of Medicine, Karadeniz Technical University, Trabzon 61080, Turkey.
  • Öztürk FA; Department of Medicinal and Aromatic Plants, Köycegiz Vocational School, Mugla Sitki Koçman University, Köycegiz, Mugla 48800, Turkey.
  • Öztürk M; Department of Chemistry, Faculty of Sciences, Mugla Sitki Koçman University, Mugla 48121, Turkey.
  • Tok TT; Department of Chemistry, Faculty of Arts and Sciences, Gaziantep University, Gaziantep 27310, Turkey.
  • Emre EEO; Department of Chemistry, Faculty of Arts and Sciences, Gaziantep University, Gaziantep 27310, Turkey.
ACS Omega ; 8(41): 38641-38657, 2023 Oct 17.
Article em En | MEDLINE | ID: mdl-37867693
ABSTRACT
This study is aimed to synthesize morpholine- and thiazolidine-based novel 5-(substituted)benzylidene)-2-(morpholinoimino)-3-phenylthiazolidin-4-ones (3-26) and characterized by molecular spectroscopy. The synthesized compounds were subjected to antioxidant activity with anticholinesterase, tyrosinase, and urease inhibition activities and evaluated the structure-activity relationship (SAR) of enzyme inhibition activities. Compound 11 was found to be the most active antioxidant. In anticholinesterase inhibition, compound 12 (IC50 17.41 ± 0.22 µM) was the most active against AChE, while compounds 3-26 ( except 3, 8, and 17) showed notable activity against BChE. Compounds 17 (IC50 3.22 ± 0.70 mM), 15 (IC50 5.19 ± 0.03 mM), 24 (IC50 7.21 ± 0.27 mM), 23 (IC50 8.05 ± 0.11 mM), 14 (IC50 8.10 ± 0.22 mM), 25 (IC50 8.40 ± 0.64 mM), 26 (IC50 8.76 ± 0.90 mM), and 22 (IC50 9.13 ± 0.55 mM) produced higher tyrosinase inhibition activity. In urease inhibition activity, compounds 20 (IC50 16.79 ± 0.19 µM), 19 (IC50 18.25 ± 0.50 µM), 18 (IC50 20.24 ± 0.77 µM), 26 (IC50 21.51 ± 0.44 µM), 25 (IC50 21.70 ± 0.06 µM), and 24 (IC50 22.49 ± 0.11 µM) demonstrated excellent activities. Besides, the molecular docking study was applied to better understand the inhibitory mechanism between (1-26) compounds and enzymes at the molecular level. According to the results of this study, the synthesized compounds exhibited a better binding affinity toward these enzymes compared to the positive control. Further, molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) binding free energy and molecular dynamics (MD) simulation analyses were performed for AChE with compound 26, which showed high inhibitory activity in silico and in vitro studies. In conclusion, novel morpholine and thiazolidine-based derivative compounds may be pharmacologically effective agents for AChE, BChE, tyrosinase, and urease enzymes.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Omega Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Turquia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Omega Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Turquia